目的 探討天麥消渴片聯(lián)合羅格列酮治療2型糖尿病的臨床療效。方法 選取2014年3月-2015年11月在上海市普陀區(qū)中心醫(yī)院接受治療的2型糖尿病患者86例,隨機(jī)分為對(duì)照組和治療組,每組各43例。對(duì)照組口服羅格列酮鈉片,1片/次,1次/d,最大劑量為2片/d。治療組在對(duì)照組基礎(chǔ)上口服天麥消渴片,2片/次,2次/d。兩組患者均連續(xù)治療12周。觀察兩組治療后臨床療效,比較治療前后血脂、血糖、胰島素分泌指數(shù)(HOMA-β)、胰島素抵抗指數(shù)(HOMA-IR)、血清腫瘤壞死因子-α(TNF-α)和白細(xì)胞介素-6(IL-6)水平變化情況。結(jié)果 治療后,對(duì)照組與治療組有效率分別為76.74%、93.02%,兩組差異比較有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,兩組TG、TC和LDL-C均明顯降低,HDL-C升高,與治療前比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療組的TC、TG、LDL-C和HDL-C改善程度均明顯優(yōu)于對(duì)照組(P<0.05)。治療后,兩組FPG、2 h PG和HbAlc水平比治療前均明顯降低(P<0.05);且治療組降低程度優(yōu)于對(duì)照組(P<0.05)。治療后,兩組患者HOMA-β升高,HOMA-IR降低,與治療前比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療組HOMA-β和HOMA-IR的改善程度優(yōu)于對(duì)照組,差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,兩組患者血清TNF-α、IL-6含量均較同組治療前顯著降低(P<0.05);且治療組比對(duì)照組降低的更顯著(P<0.05)。結(jié)論 采用天麥消渴片聯(lián)合羅格列酮治療2型糖尿病療效顯著,可明顯改善胰島素抵抗和提高胰島素敏感性,有利于糾正血脂異常和減輕機(jī)體炎癥反應(yīng)狀態(tài),具有一定的臨床應(yīng)用推廣價(jià)值。

ObjectiveTo observe the clinical efficacy of Yangzheng Xiaoji Capsules combined with FOLFIRI scheme in treatment of colorectal cancer. Methods Patients (84 cases) with colorectal cancer who received surgical treatment in Shaanxi Provincial Tumor Hospital from April 2013 to March 2015 were numbered according to the order of registration and admission, and divided into the control group and treatment group according to the random number table method, and each group had 42 cases. The patients in the control group were treated by FOLFIRI chemotherapy scheme. The patients in the treatment group were po administered with Yangzheng Xiaoji Capsules, 4 capsules/time, three times daily. The patients in two groups were treated for two courses. After treatment, the clinical efficacies were evaluated, and the changes of T lymphocyte subsets (CD³⁺, CD⁴⁺, and CD⁸⁺) and NK cell activity were compared between the two groups. In the same time, incidence of adverse reactions and improvement of quality of life between two groups were analyzed. Results After treatment, the clinical efficacies in the control and treatment groups were 61.90% and 85.71%, respectively, and there was difference between two groups (P < 0.05). After treatment, CD³⁺, CD⁴⁺ and NK activity of the treatment group were significantly increased, while CD⁸⁺ activity was decrease, and the difference was statistically significant in the same group (P < 0.05). And those immune function indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the incidence rates of myelosuppression and constipation in the treatment group were 2.38% and 4.76%, and lower than those in the control group (P < 0.05). The incidence rates of nausea/vomiting, hepatorenal dysfunction, diarrhea, and mucosal inflammation were slightly lower than those in the control group, but the differences were not statistically significant. After treatment, KPS score in the treatment group were significantly increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the rise ranges in the treatment group higher than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Yangzheng Xiaoji Capsules combined with FOLFIRI scheme has clinical curative effect in the treatment of colorectal cancer, can strengthen immunity, improve the quality of life of patients, is less adverse reactions, which has a certain clinical application value.